Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A recent study published by Prof Najib Rahman, Clinical Director, Oxford Respiratory Trials Unit explains how 15% of people with malignant effusion develop septations (pockets) within the fluid, which are difficult to treat.

TIME3 was a randomised trial assessing the use of intrapleural fibrinolytic, showing no improvement in breathlessness but improved x-ray appearance and possible mortality benefit. This study provides high quality evidence for the rational use of this medication for patients.

Read the full article